Solid Tumor Research: Ongoing CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin’s lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma), acute lymphoblastic leukemia (ALL), chronic …
CAR T-Cell Therapy HCP Guide – Solid Tumors Read More
ZUMA-3 and ZUMA-4 Trials In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients with ALL. As reported in …
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials Read More
Use of Yescarta in Acute Lymphoblastic Leukemia Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute lymphoblastic leukemia (r/r ALL). ALL is …
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia Read More
October 17, 2017 (Medical News Today) Scientists and researchers from the UK have set out to investigate why cancer often returns in patients whose cancers have become dormant, focusing especially …
Cancer recurrence may be stopped with immunotherapy Read More
Creating a universal CAR T agent could help avoid the lengthy and sometimes dangerous time period from apheresis of T-cells to re-infusion, which on average runs 2 to 2.5 weeks, …
CAR T-Cell Therapy HCP Guide – Is There A Universal CAR-T Cell Therapy? Read More
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have exhausted their cancer treatment options, and …
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy? Read More
At a July 2017 FDA Oncology Advisory Committee meeting, the panel reviewed Novartis’ CTL019 (tisagenlecleucel), an agent for aggressive pediatric and young adult acute B-cell acute lymphoblastic leukemia (ALL). The …
CAR T-Cell Therapy HCP Guide – Is CAR T-Cell Therapy Approved? Read More
CAR T-Cell FDA Approval: Status Update In addition to the approval of Kymriah, Yescarta (axicabtagene ciloleucel or Axi-Cel) was approved on October 18, 2017 for the treatment of adult patients …
CAR T-Cell Therapy HCP Guide – Updates from the FDA Read More
Published September 18, 2017 CAR T-cell therapy is a revolutionary immunotherapy treatment that supercharges a patient’s own blood cells to seek out and destroy cancer cells. Thanks to CAR T-cell …
VIDEO: CAR T-cell Therapy for Pediatric Leukemia: Sam’s Story Read More
September 6, 2017 (HealthDay News) In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy Outcomes of treatment with third-generation CAR T-cell therapy in CD19-positive B-cell malignancy are associated with …
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy Read More